DOCS Q2 Deep Dive: AI Product Adoption Fuels Revenue Growth, Margins Face Investment Pressures
Doximity reported Q2 revenue of $156.6M, up 7.3% year over year and above analysts’ $151.3M estimate. Adjusted EBITDA was $74.77M versus $69.59M, but adjusted EPS was $0.29 versus $0.30. The company slightly lifted full-year revenue guidance to $676M midpoint, while EBITDA guidance of $319M trails estimates. Management cited AI product adoption and NOHARM study validation, alongside higher AI investment pressuring margins.
How this was made
The 30-second read
Why it matters
Traders can update models using the specific guidance changes: full-year revenue midpoint raised to $676M from $670M, while full-year EBITDA midpoint lowered to $319M versus $329.1M consensus; operating margin fell sharply year over year amid AI investment.
Market read
AI adoption metrics (physician engagement, prompt volume, AI Scribe growth) support demand signals, but the guidance mix and margin compression create a two-sided setup for near-term positioning.
What to watch
The article cites NOHARM study validation and contract lengthening, but does not quantify churn, pricing, or gross margin trajectory beyond management’s mid-to-high 80% gross margin expectation.
Background
The piece is a Q2 earnings deep dive focused on Doximity’s AI product adoption (Ask, AI search, AI Scribe) and how it is translating into revenue, billings, and contract evolution.
Ticker impact
Doximity reported Q2 revenue of $156.6M, lifted full-year revenue guidance to $676M, but cut EBITDA guidance to $319M midpoint.
Near-term volatility likely as investors weigh upside from AI monetization against the EBITDA guidance miss and operating margin decline.
The article provides multiple forward-looking datapoints (revenue guide up, EBITDA guide down) plus a clear margin bridge (operating margin down to 21.5% from 37.4%).
Market effects
Reinforces the market narrative that clinical AI adoption can drive engagement and new enterprise contracts, but profitability may lag due to upfront infrastructure costs.
No specific regional impact described beyond US hospital and pharma client demand.
Limited, as the disclosed traction and study validation are framed around US clinical AI and enterprise buyers.
Counterpoint
The EBITDA guidance shortfall and operating margin collapse could indicate AI monetization is not yet scaling enough to offset cost growth, making the revenue guide lift less durable.
Key entities
- companyDoximity
US clinical network monetizing AI products; reported Q2 results and updated full-year revenue and EBITDA guidance.
- studyNOHARM study
Independent validation cited by management to support safety and reliability of Doximity’s Ask product.
